Investors gel with Shanghai Haohai IPO

Chinese small cap biomedical materials producer poised to benefit from liquidity-fuelled rally pushing Hong Kong stocks closer to A-share valuations.

Investors gel with Shanghai Haohai IPO

Biomedical materials producer Shanghai Haohai Biological Technology wraps up pre-marketing on Tuesday for a $250 million to $350 million initial public offering, which looks set to benefit from the liquidity fuelled rally that has been pushing the valuations of Hong Kong listed stocks closer to their Mainland counterparts. 

The deal has been on an accelerated schedule after commencing investor education last Wednesday and appears to have hit a sweet spot in the market. The...

To continue reading, please login or register for free

Click for more on: china | hong kong | ipo | ubs | markets | health

Print Edition

FinanceAsia Print Edition


  • Green Bonds Southeast Asia

    25 May 2017  |  Singapore
    With Green Bonds globally reaching USD200 billion outstanding in 2016, from as little as 30bn just 4 years ago, can SE Asia corporations and ...
  • 2nd Compliance Summit Southeast Asia

    17 August 2017  |  Singapore
    The 2017 Compliance Summit Southeast Asia will take an in-depth look at the key compliance considerations today with a focus on regulation and new ...